Features of Patients Referring to the Outpatient Office Due to Benign Prostatic Hyperplasia: Analysis of a National Prospective Cohort of 5815 Cases

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2022 Jul 22

PMID 35869394

Authors

Paola Irene Ornaghi

Angelo Porreca

Marco Sandri

Alessandro Sciarra

Mario Falsaperla

Giuseppe Mario Ludovico

Maria Angela Cerruto

Alessandro Antonelli

Affiliations

Soon will be listed here.

Abstract

Background: Evidence on clinical presentation of benign prostatic hyperplasia (BPH) is scarce, and studies involving outpatients are lacking. We aimed to provide an insight into the contemporary Italian scenario of BPH-affected outpatients using symptom scores (International Prostate Symptom Score [IPSS], BPH Impact Index [BII]), and to compare characteristics of patients with known BPH and those first-diagnosed at the visit.

Methods: "IMPROVING THE PATH" project working group designed a questionary prospectively administered to BPH-affected outpatients by urologists. A cross-sectional study was performed. Data were adjusted for patient age as a potential confounding factor.

Results: Of 5815 patients enrolled, BPH was already diagnosed in 4144 (71.3%), and not in 1671 (28.7%). Patients with known BPH, compared to newly diagnosed, were older (median 68 versus [vs] 55), had more frequent smoking (smoker 27.2 vs 22.6%, and ex-smoker 16.4 vs 12.5%) and drinking habits (55.4 vs 45.1%), were more frequently affected by hypertension (60.0 vs 42.4%), obesity (15.3 vs 9.6%), diabetes (17.9 vs 12.5%), and cardiovascular diseases (14.2 vs 9.5%), p < 0.001. At IPSS, moderate and severe symptoms correlated with already known BPH (56.1 vs 47.3% and 24.8 vs 7.8%), whereas newly diagnosed patients showed milder symptoms (44.9 vs 19.1%), all p < 0.001. At BII, concern for one's health and time lost due to urinary problems were higher in patients with known BPH (p < 0.001). For these patients, the urologist changes at least one of the ongoing medications in 63.5%. For patients newly diagnosed, supplements/phytotherapeutics, alpha-blockers, and 5-alfa reductase inhibitors were prescribed in 54.6%, 21.6%, and 7.1%, respectively.

Conclusions: Despite medical treatment, natural history of BPH leads to a progressive deterioration of symptoms. This may reflect the difference between newly diagnosed patients and those with known BPH in lifestyle and associated comorbidities. A healthy lifestyle and treatments including local anti-inflammatory agents may delay worsening of symptoms and improve quality of life.

Citing Articles

Efficacy and safety of prostatic urethral lift according to preoperative urinary retention and prostate volume: A Japanese real-world multicenter data.

Anan G, Minami H, Fujishima Y, Kaga K Int J Urol. 2024; 32(2):190-197.

PMID: 39501555 PMC: 11803185. DOI: 10.1111/iju.15621.

Ejaculation physiology and dysfunction after BPH surgery: the role of the new MISTs.

Sibona M, Destefanis P, Vercelli E, Secco S, Gontero P, Cindolo L Prostate Cancer Prostatic Dis. 2023; 26(3):475-482.

PMID: 37500787 DOI: 10.1038/s41391-023-00686-y.

Patients' Preferences and Expectations in Overactive Bladder: A Systematic Review.

Cicione A, Lombardo R, Umbaca V, Tema G, Gallo G, Stira J J Clin Med. 2023; 12(2).

PMID: 36675324 PMC: 9864850. DOI: 10.3390/jcm12020396.

References

Devlin C, Simms M, Maitland N . Benign prostatic hyperplasia - what do we know?. BJU Int. 2020; 127(4):389-399. DOI: 10.1111/bju.15229. View

Vuichoud C, Loughlin K . Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015; 22 Suppl 1:1-6. View

Rhodes T, Girman C, Jacobsen S, Roberts R, Guess H, Lieber M . Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999; 161(4):1174-9. View

Madersbacher S, Haidinger G, Temml C, Schmidbauer C . Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol. 1998; 34(2):136-41. DOI: 10.1159/000019699. View

Madersbacher S, Sampson N, Culig Z . Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology. 2019; 65(5):458-464. DOI: 10.1159/000496289. View

Choi W, Son H . The change of IPSS 7 (nocturia) score has the maximum influence on the change of Qol score in patients with lower urinary tract symptoms. World J Urol. 2018; 37(4):719-725. DOI: 10.1007/s00345-018-2410-8. View

Albisinni S, Aoun F, Roumeguere T, Porpiglia F, Tubaro A, De Nunzio C . New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review. Minerva Urol Nefrol. 2016; 69(2):119-132. DOI: 10.23736/S0393-2249.16.02743-0. View

Barry M, Fowler Jr F, OLeary M, Bruskewitz R, HOLTGREWE H, MEBUST W . The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992; 148(5):1549-57; discussion 1564. DOI: 10.1016/s0022-5347(17)36966-5. View

Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J . Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009; 181(4):1779-87. DOI: 10.1016/j.juro.2008.11.127. View

10.

Barry M, Fowler Jr F, OLeary M, Bruskewitz R, HOLTGREWE H, MEBUST W . Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care. 1995; 33(4 Suppl):AS145-55. View

11.

Mobley D, Feibus A, Baum N . Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. Postgrad Med. 2015; 127(3):301-7. DOI: 10.1080/00325481.2015.1018799. View

12.

OLeary M, Wei J, Roehrborn C, Miner M . Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int. 2008; 101(12):1531-5. DOI: 10.1111/j.1464-410X.2008.07574.x. View

13.

Kingery L, Martin M, Naegeli A, Khan S, Viktrup L . Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient. Int J Clin Pract. 2012; 66(9):883-90. DOI: 10.1111/j.1742-1241.2012.02960.x. View

14.

Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N . α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies. Eur Urol. 2016; 69(6):1091-101. DOI: 10.1016/j.eururo.2015.12.034. View

15.

Sebastianelli A, Spatafora P, Morselli S, Vignozzi L, Serni S, McVary K . Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. Curr Urol Rep. 2020; 21(12):56. PMC: 7591403. DOI: 10.1007/s11934-020-01009-7. View

16.

Hong S, Min G, Ha S, Doo S, Kang M, Park H . Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU Int. 2009; 105(7):970-4. DOI: 10.1111/j.1464-410X.2009.08915.x. View

17.

Joo K, Sung W, Park S, Yang W, Kim T . Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. J Int Med Res. 2012; 40(3):899-908. DOI: 10.1177/147323001204000308. View

18.

Roehrborn C, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I . The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2009; 57(1):123-31. DOI: 10.1016/j.eururo.2009.09.035. View

19.

Roehrborn C, Oyarzabal Perez I, Roos E, Calomfirescu N, Brotherton B, Wang F . Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the.... BJU Int. 2015; 116(3):450-9. DOI: 10.1111/bju.13033. View

20.

Choi J, Kim J, Ahn S . Transitional Zone Index as a Predictor of the Efficacy of α-Blocker and 5α-Reductase Inhibitor Combination Therapy in Korean Patients with Benign Prostatic Hyperplasia. Urol Int. 2016; 96(4):406-12. DOI: 10.1159/000442995. View